| Name | Title | Contact Details |
|---|---|---|
Kevin Lawler |
Senior Director Admin/Human Resources | Profile |
Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered treatment that exploits intrinsic TME-specific metabolites, enabling selective enrichment of the bacterial vehicle in tumors. After cell-specific entry, our lead candidate, ACTM-838, positively activates tumor-resident myeloid cells and delivers two synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive anti-tumor immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.
Eyetech Pharmaceuticals, Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Nutripro Biosystems is a Worthington, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Newlight Technologies is a company based in Irvine, California known for carbon sequestration into plastics.
Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.